Navigation Links
Omeros Unlocks Four Additional Orphan GPCRs
Date:9/13/2011

l libraries using its proprietary, high-throughput cellular redistribution assay (CRA). Omeros has announced that it has identified and confirmed sets of compounds that interact selectively with 14 orphan receptors linked to esophageal squamous cell carcinoma and obesity-related type-2 diabetes (GPR39), squamous cell carcinoma (GPR87), pancreatic cancer (GPR182), acute lymphoblastic leukemia (P2Y8/P2RY8), sleep disorders (OPN4), cognitive disorders (GPR12), bipolar disorder and schizophrenia (GPR78), psychotic and metabolic disorders (GPR27, GPR85, GPR173), appetite control (GPR101), rheumatoid arthritis and HIV-mediated enteropathy (GPR15), motor control (GPR139) and congenital cataracts and birth defects of the brain and spinal cord (GPR161). The CRA detects receptor antagonists and agonists. Antagonists comprise the majority of marketed drugs, and all of the compounds characterized so far by Omeros are antagonists.

About G Protein-Coupled Receptors

GPCRs, which mediate key physiological processes in the body, are one of the most valuable families of drug targets. According to Insight Pharma Reports, GPCR-targeting drugs represent 30 to 40 percent of marketed pharmaceuticals. Examples include Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics.  

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Wit
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
2. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
3. Omeros Announces Clinical Development Programs for OMS103HP and OMS302
4. Omeros Corporation Reports First Quarter 2011 Financial Results
5. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
6. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
7. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
8. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
9. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
10. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
11. Omeros Announces Publication of Data From Antifibrinolytic Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... September 4, 2015 According to ... (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic ... Product - Global Forecast to 2020", published by MarketsandMarkets, ... 2.5 Billion by 2020, growing at a CAGR of ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... JERUSALEM , September 4, 2015 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... the Company will participate in the upcoming Rodman & ... place September 8-10, 2015 in New York ... of Oramed, will present a corporate overview on September ...
(Date:9/4/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted its seventh abbreviated new ... Administration (FDA) of 2015, which brings the Company,s total ... to twenty-nine. Jason Grenfell-Gardner , President ... current pipeline of twenty-nine submissions, exclusive of our four ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2
(Date:9/4/2015)... ... ... The Schmidt National Law Group filed an Essure® lawsuit against Bayer and ... Group, a leading firm in mass-tort litigation, has filed a lawsuit in the federal ... other Bayer affiliates for injuries alleged to have been caused by her Essure® contraceptive ...
(Date:9/4/2015)... ... September 04, 2015 , ... Georgia ... is launching a charity effort to provide for the family of Grace, a ... enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the inability to ...
(Date:9/4/2015)... Monroe, NC (PRWEB) , ... September 04, 2015 ... ... Girl’s Night out to benefit Core Compassion Project. Core Compassion Project is ... a specialized program to reduce the side effects of cancer treatments and recover ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... that CEREC technology is now available at CitiDent. CEREC is a newer method ... addition to saving time for patients by eliminating the need for multiple appointments, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2
... Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: ... provider of pharmacy benefits management technology and services, ... maintenance and professional services agreements, and a software ... The agreements provide Prime with software licensing, software ...
... Chia Seed Flour is the buzz when it comes to ... Seed Flour is made from the tiny chia seeds. The ... It is the most nutritious grain available today. Now, thanks ... Flour is once again available for dinner tables everywhere. It ...
... Industry-leading and renowned laparoscopic bariatric surgeon Dr. ... selected by medical device manufacturers to introduce a ... County Region.Dr. Smith continues to lead the way ... as SILS (Single Incision Laparoscopic Surgery), at Specialty ...
... SAO PAULO and PHILADELPHIA, May 20 moksha8, Inc. ... with Roche to commercialize an additional portfolio of products ... , , moksha8 will commercialize products in ... The product portfolio consists of well-known brands including Rivotril(R), ...
... Area high schoolers take to the stage at the House of ... most creative seat belt messagesCLEVELAND, May 20 Local teens had ... -- at the House of Blues at noon on Tuesday, May ... Lose It High School Seat Belt Challenge, sponsored by Kohl,s, ...
... May 20 A three-minute video gave Midwesterners all the ... when Kansas City Public Television aired "Imagine KC." The video ... for the benefit of all. The project is the latest ... KC-based studio which has successfully marketed over $6 Billion in ...
Cached Medicine News:Health News:SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC 2Health News:SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC 3Health News:SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC 4Health News:Nuchia Foods' Gluten-Free Chia Seed Flour Is a Tasty, Low-Fat Alternative Flour 2Health News:Nuchia Foods' Gluten-Free Chia Seed Flour Is a Tasty, Low-Fat Alternative Flour 3Health News:Dr. Adam Smith Chosen to Help Introduce No-Scar Surgical Weight-Loss Innovations 2Health News:moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico 2Health News:Rainbow Babies & Children's Hospital's Use It or Lose It High School Seat Belt Challenge Brings Out the Creativity in Cuyahoga County Teens 2Health News:Rainbow Babies & Children's Hospital's Use It or Lose It High School Seat Belt Challenge Brings Out the Creativity in Cuyahoga County Teens 3Health News:Arnold Imaging Video Generates Public Enthusiasm for Light Rail 2
... VERSASTEP™ Plus Short Instrument ... , ,The VERSASTEP™ Plus ... Working Length is a unique ... applications in laparoscopic procedures. It ...
... Trocar consists of a blunt obturator connected ... assembly. , ,The valve body assembly ... to prevent gas leakage when instruments are ... Trocar includes built-in converters to allow insertion ...
... Premium One-Step™ single-use system device is comprised ... device components for creating each access port ... , Step™ insufflation and access needle, ... separately. , Step™ radially expandable sleeve, 100 ...
... contains an internal seal to prevent gas leakage ... of pneumoperitoneum. The 5 mm PLUS system includes ... mm - 12 mm as appropriate and is ... of the trocar to allow insertion of smaller ...
Medicine Products: